

## AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previous versions, and listings, of claims pending in this application.

### Listing of Claims

This listing of claims replaces all previous versions, and listings, of claims pending in this application.

### Listing of Claims

1-161. (Canceled)

162. (Currently amended) A compound comprising a peptide chain having a sequence of amino acids  $CX^{IV}_1X^{IV}_2X^{IV}_3X^{IV}_4X^{IV}_5X^{IV}_6X^{IV}_7X^{IV}_8X^{IV}_9X^{IV}_{10}C$  that binds to a G-CSFR, wherein said sequence of amino acids is selected from the group consisting of GGGLLDICELKLQECARRCN (SEQ ID NO: 209); GRTGGLLDICELKLQECARRCN (SEQ ID NO: 210); LGIEGRTGGGLLDICELKLQECARRCN (SEQ ID NO: 211); ~~LLDICEELKLQEAARRCN~~ and ~~LLDICELKLQEAARRCN~~ (SEQ ID NO: 212); ~~LLDIAELKLQECARRCN~~ (SEQ ID NO: 464); and ~~LLDICELKLQECARRAN~~ (SEQ ID NO: 343), and wherein each amino acid is indicated by standard one-letter abbreviation.

163. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is GGGLLDICELKLQECARRCN (SEQ ID NO: 209).

164. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is GRTGGLLDICELKLQECARRCN (SEQ ID NO: 210).

165. (Canceled)

166. (Previously presented) The compound of claim 162, containing a disulfide bond.

167. (Previously presented) The compound of claim 162 wherein the N terminus of the peptide is coupled to a polyethylene glycol molecule.

168. (Previously presented) The compound of claim 162 wherein the N terminus of the peptide is acetylated.

169. (Previously presented) The compound of claim 162, wherein the C terminus of the peptide is amidated.

170. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 162, in combination with a pharmaceutically acceptable carrier.

171. (Withdrawn – currently amended) A method for treating a patient who would benefit from administration of a GCSF modulator, comprising administering to the patient a therapeutically effective amount of the compound of any one of claims 162, 179, and 180. ~~claim 162.~~

172. (Withdrawn) The method of claim 171, wherein the G-CSF modulator is an agonist for the GCSFR.

173. (Withdrawn) The method of claim 171, wherein the patient suffers from a depressed neutrophil count.

174. (Withdrawn) The method of claim 173, wherein the depressed neutrophil count is associated with a condition selected from the group consisting of chemotherapy-induced neutropenia, AIDS induced neutropenia and community-acquired pneumonia-induced neutropenia.

175. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is LGIEGRTGGGLLDICELKLQECARRCN (SEQ ID NO: 211).

176. (Currently amended) The compound of claim 162, wherein said sequence of amino acids is ~~LLDICEELKLQEAARRCN~~ LLDICELKLQEAARRCN (SEQ ID NO: 212).

177-178. (Canceled)

179. (New) A compound comprising a peptide chain having a sequence of amino acids  $X^{VI}_1X^{VI}_2X^{VI}_3X^{VI}_4X^{VI}_5EX^{VI}_6X^{VI}_7X^{VI}_8X^{VI}_9$  that binds to a G-CSFR, wherein said sequence of

amino acids is LLDIAELKLQECARCN (SEQ ID NO:464), and wherein each amino acid is indicated by standard one-letter abbreviation.

180. (New) A compound comprising a peptide chain having a sequence of amino acids  $X^V_1X^V_2X^V_3X^V_4X^V_5X^V_6CX^V_7X^V_8$  that binds to a G-CSFR, wherein said sequence of amino acids is LLDICELKLQECARRAN (SEQ ID NO:343), and wherein each amino acid is indicated by standard one-letter abbreviation.

181. (New) The compound of claim 179 or 180, containing a disulfide bond.

182. (New) The compound of claim 179 or 180 wherein the N terminus of the peptide is coupled to a polyethylene glycol molecule.

183. (New) The compound of claim 179 or 180 wherein the N terminus of the peptide is acetylated.

184. (New) The compound of claim 179 or 180, wherein the C terminus of the peptide is amidated.